PATIENT CHARACTERISTIC OF SURGICAL TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN THE CITY Of SEMEY SITY: A COHORT STUDY
Aim: The study was done to evaluate pre-operative factors, which influence the post-operative outcome in patients undergoing surgery for Benign Prostatic Hyperplasia (BPH)
Materials and methods: Setting and Design: It was carried out retrospectively at Semey city East Kazakhstan region.
Retrospective cohort study of outcomes of 782 patients with BPH who underwent surgical treatment in the Semei Kidney Center, East Kazakhstan region from 2017 to 2019. All the information was collected from case files of patients. Descriptive statistics were used to analyze the data. For qualitative data Pearson’s Chi-square was used.
Results: Most of the patients were admitted to hospital by emergency ambulance, half of the patients had received conservative treatment before, the majority of the patients had delay between the first symptoms and the first present in hospital, patients had one – two diseases as comorbid condition, overweight. The average length of stay in hospital was 10-15 days. Half of patients (53.2%) after treatment recovered, condition improved at 35.8% patients, condition deteriorated at 7.2% patients, without changes were 3.8% patients. Our study defined significant difference between age group (p=0.005), way of admission to hospital (p=0.003), self-referral (p=0.000), severity of condition (p=0.000), comorbid condition (p=0.000), length of hospital stay (p=0.000) and surgical treatment outcomes. There was no significant difference between nationality (p=0.052), rural / urban status (p=0.146), social position (p=0.146), BMI (p=0.411) history of conservative treatment (p=0.064) and surgical treatment outcomes
Conclusion: Aged patients, patients who were admitted to hospital through the unplanned emergency way, self-referral patients had worse outcomes after surgery. Delaying intervention can lead to BPH progression and poorer outcomes. Condition was not changed and deteriorated in patients whom delay was more than a month
Asset M. Kussainov1, https://orcid.org/0000-0002-8816-5357;
Gulnar M. Shalgumbayeva1, https://orcid.org/0000-0003-3310-4490
Tolkyn A. Bulegenov1, https://orcid.org/ 0000-00016145-9649;
Куат Д. Акимжанов1, https://orcid.org/ 0000-0002-8608-0771
Ainash B. Salmenbaeva1, Malika E. Musulmanbek1
1 NJSC "Semey Medical University",
Semey, Republic of Kazakhstan.
1. Gravas S., Cornu J.N., Drake M.J., Gacci M., Gratzke C., Herrmann T.R.W., et al. Management of non-neurogenic male lower urinary tract symptoms (LUTS). Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-the-Management-of-Non-neurogenic-Male-LUTS-2018-large-text.pdf. (accessed: March 2018)
2. Calogero A.E., Burgio G., Condorelli R.A., Cannarella R., La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms / benign prostatic hyperplasia and erectile dysfunction // The Aging Male. 2019. 22(1):12-19
3. Bishr M., Boehm K., Trudeau V. et al. Medical management of benign prostatic hyperplasia: Results from a populationbased study // Can Urol Assoc J. 2016.10:55-9
4. Davidian Michael H. Guidelines for the treatment of benign prostatic hyperplasia // US Pharm. 2016. 41.8: 36-40.
5. Kuebker J.M., Miller N.L. Holmium Laser Enucleation of the Prostate: Patient Selection and Outcomes // CurrUrol Rep. 2017. 18:96.
6. Ben-Zvi T., Hueber P. A., Liberman D., Valdivieso R., Zorn K.C. Green Light XPS 180W vs HPS 120W laser therapy for benign prostate hyperplasia: a prospective comparative analysis after 200 cases in a single-center study // Urology. 2013. 81(4): 853-858.
7. Lokeshwar A.M. et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia // Transl Androl Urol. 2019. 8(5):529-539 http://dx.doi.org/10.21037/tau.2019.10.01
8. Tanriverdiev O., Kiselev I.V. Modern methods of treatment and prevention of benign prostatic hyperplasia // Bulletin of Science. 2020. 5(5) (26): 286-289.
9. Bugaev E.A., Tulaev B.B. Treatment of benign prostatic hyperplasia and prostate inflammatory processes // Bulletin of Surgery of Kazakhstan. 2013. 1 (33): 61-64.
10. Vuichoud C., Loughlin K.R. Benign Prostatic Hyperplasia: epidemiology, economics and evaluation // Can J Urol. 2015. 22 (Suppl 1):1-6. https://www.ncbi.nlm.nih.gov/pubmed/26497338. (accessed: 15.07.2022)
11. Albisini Simone, Fouad Aoun, Thierry Roumeguere, Francesco Porpiglia, Andrea Tubaro. New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review // Minerva Urologica e Nefrologica. 2017 April, 69(2):19-32
12. Kalinov D. The Role of General Practitioners in Prescribing Prostate-Specific Antigen Testing for Early Detection and Treatment of Benign Prostate Hyperplasia // J Med Sci. 2022 Aug.12 10(E):1588-92. Available from: https://oamjms.eu/index.php/mjms/article/view/10369 [cited 2022 Oct. 26]
13. Egan K.B., Suh M., Rosen R.C., Burnett A.L., Ni X., Wong D.G., McVary K.T. Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008 // Int J ClinPract. 2015. Nov, 69(11):1316-25. doi: 10.1111/ijcp.12709. Epub 2015 Jul 28. PMID: 26215544.
14. Seong Ho Lee, Sang Kon Lee. Does race/ethnicity have a role in a link between lower urinary tract symptoms and metabolic syndrome? EMJ. 2017;2[1]:69-75
15. Han X.F., Ren J.L., Hu L.M., Chen F.R., Xu K.X. Prevalence of benign prostatic hyperplasia in Pingliang // Gansu: investigation and clinical analysis Zhonghua Nan KeXue. 2013.19:4:324-327
16. Fowke J.H., Murff H.J., Signorello L.B., Lund L., Blot W.J. Race and Socioeconomic Status are Independently Associated with Benign Prostatic Hyperplasia (BPH) // J Urol. 2008 November; 180(5): 2091–2096. doi:10.1016/j.juro.2008.07.059
17. Lokeshwar S.D., Harper B.T., Webb E., Jordan A., Dykes T.A., Neal Jr., Klaassen Z. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Translational andrology and urology. 2019. 8(5):529.
18. Elkoushy M.A., Elshal A.M., Elhilali M.M. Changing patients’ profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: A single-centre perspective // Can Urol Assoc J. 2015 Nov-Dec, 9(11-12):372-8
19. Parsons J.K., Sarma A.V., McVary K., Wei J.T. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions // J Urol. 2013. Jan, 189(1Suppl):S102-6. doi: 10.1016/j.juro.2012.11.029. PMID: 23234610
Number of Views: 54
Category of articles:
Original articles
Bibliography link
Kussainov A.M., Shalgumbayeva G.M., Bulegenov T.A., Акимжанов К.Д., Salmenbaeva A.B., Musulmanbek M.E. Patient Characteristic of surgical treatment of benign prostatic hyperplasia in the city of Semey: a cohort study // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 3, pp. 121-127. doi 10.34689/SH.2023.25.3.016Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS